Pan Pacific Lymphoma Conference | Conference

P53-Mutated MCL Remains Difficult to Treat

July 22nd 2022

Mutations in the p53 gene are associated with poor prognosis for patients with mantle cell lymphoma. Although modern regimens have improved outcomes, those treatments are associated with significant toxicity and, so far, have produced limited efficacy.

BiTEs, CAR T-Cell Therapy, and ADCs Offer Variety of Lymphoma Treatment Options, But Questions Remain

July 22nd 2022

An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.

ASCT No Longer Suitable for the Majority of Patients with DLBCL

July 22nd 2022

Most patients with diffuse large B-cell lymphoma do not derive significant benefit from treatment with autologous stem cell transplantation and better therapeutic options are currently available for this population.

Zanubrutinib Displays Improved Efficacy Vs Orelabrutinib in Relapsed/Refractory CLL/SLL and MCL

July 22nd 2022

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.

Dr. Brody on Second-Line CAR T-cell Therapy in DLBCL

July 22nd 2022

Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.

Dr. D’Angelo on Emerging Therapies in DLBCL

July 21st 2022

Christopher R. D’Angelo, MD, discusses emerging therapies in diffuse large B-cell lymphoma.

Westin and Sehn Carve Out the Role of CAR T-Cell Therapy and Transplant in Primary Refractory DLBCL

July 21st 2022

CAR T-cell therapy, autologous stem cell transplant, and novel agents each have a role to play in the second-line management of patients with primary refractory diffuse large B-cell lymphoma, according to Jason Westin, MD, MS, FACP, and Laurie H. Sehn, MD, MPH.

Pooled Real-World Data Support Earlier Line Use of IRd in Relapsed/Refractory Multiple Myeloma

July 21st 2022

A pooled analysis of the INSIGHT MM, UVEA-IXA, and REMIX observational studies found that real-world outcomes with ixazomib/lenalidomide/dexamethasone were consistent with those reported in the TOURMAILINE-MM1 study.

Increased Treatment Efficacy in p53-Mutated MCL Remains Elusive

July 21st 2022

Tycel Jovelle Phillips, MD, outlines the reasons why p53-mutated mantle cell lymphoma is difficult to treat and discusses potential future directions for the treatment of this subgroup of patients.

Multidisciplinary Team Approach Is Ideal for irAE Management in Follicular Lymphoma

July 21st 2022

Immune checkpoint inhibitor therapy in relapsed follicular lymphoma can induce immune-related adverse events which can be difficult to diagnose and manage.

Adding Novel Agents to Established Chemotherapy Regimens Key to Expanding Frontline Treatment of Classic Hodgkin Lymphoma

July 21st 2022

Alison J. Moskowitz, MD, explains how the addition of novel agents to established chemotherapy regimens could further shift the frontline treatment paradigm for classic Hodgkin lymphoma.

Brentuximab Vedotin Boosts Survival in Adult and AYA Patients with Advanced Hodgkin Lymphoma

July 20th 2022

Ann S. LaCasce, MD, MMSC, explains how bretuximab vedotin has produced a survival benefit in patients with advanced classic Hodgkin lymphoma.

Dr. Phillips on p53 Mutations in MCL

July 20th 2022

Tycel Jovelle Phillips, MD, discusses the role of p53 mutations in the outcomes of patients with mantle cell lymphoma.

Dr. Kallam on the Role of BTK and PI3K Inhibitors in CNS Lymphoma

July 20th 2022

Avyakta Kallam, MBBS, discusses the role of BTK and PI3K inhibitors in the treatment of patients with central nervous system lymphoma.

Dr. Mehta-Shah on the Variations of the CHOP Regimen in PTCL

July 20th 2022

Neha Mehta-Shah, MD, MSCI, discusses variations of CHOP-based chemotherapy in peripheral T-cell lymphoma.

Mosunetuzumab Monotherapy Generates Promising Responses in Relapsed/Refractory Follicular Lymphoma

July 20th 2022

Single-agent mosunetuzumab produced a complete response rate that was greater than what has been observed with historical controls in patients with relapsed/refractory follicular lymphoma who had received at least 2 prior lines of therapy, meeting the primary end point of the expansion portion of the phase 1/2 GO29781 trial.

Dr. Kahl on the Evolving Standard of Care in MCL

July 20th 2022

Brad S. Kahl, MD, discusses current best practices for the treatment of older patients with mantle cell lymphoma, as well as where the treatment paradigm might lead in the future.

Rituximab Maintenance Therapy Continues to Provide Remission Benefit in MCL

July 20th 2022

Brad S. Kahl, MD, explains the evolution of mantle cell lymphoma treatment over the past decade and lays out the trajectory for future therapies, including the potential benefits of lenalidomide in the maintenance setting.

Zanubrutinib Showcases Superior PFS Benefit Over BR in Treatment-Naïve CLL/SLL, Including High-Risk Subsets

July 20th 2022

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.

CB-010 Exhibits Impressive Early Efficacy in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

July 20th 2022

The CAR T-cell therapy CB-010 displayed promising preliminary efficacy and safety results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma according to findings from the phase 1 ANTLER trial presented during the 2022 Pan Pacific Lymphoma Meeting.